

**\$1.148**  
NAV per unit

**7.45%**  
3 month performance  
(net of fees)

**14.81%**  
Since inception<sup>1</sup>  
(net of fees)

## Performance Update

- The Private to Public Trust was up 7.45% (net of fees) for the quarter ending June 2020. Since inception, the Trust has returned 14.81% (net of fees). This compares favourably to the ASX All Ordinaries and the Small Ordinaries which were both down 7.5% over the same period (19 August 2019 – 30 June 2020).
- The positive performance during the quarter was attributed to the successful listing of Atomo (ASX:AT1), along with the successful participation in several listed placements.
- Atomo (ASX:AT1) was our first pre-IPO / unlisted company to list from the Trust. It is up 112% since our pre-IPO investment and 70% since the IPO.
- Key placement contributors included Kycker (ASX:KYK), Firstwave Cloud Technologies (ASX:FCT) and BetMakers (ASX:BET)
- Pleasingly many of our pre-IPO and unlisted positions had very encouraging updates during the quarter, including 4DX (now called 4D Medical), Aussie Broadband, Lumitron, Spire and Koala.


## Quarterly Review

The June Quarter had a milestone achievement for the Trust, with Atomo's (ASX: AT1) successful IPO on the ASX. This was the Trust's first business to transition from a private to public company. Our investment in Atomo is a great illustration of what the Trust is looking to achieve when investing in private businesses. To summarise:

- ✓ We identify and then invest in private businesses that satisfy our criteria of; excellent management teams, a strong product already in market and a business we think would be a great public company at some stage. In the March 2020 quarterly update we detailed why Atomo satisfied our criteria.
- ✓ We look to support the company in their transition from a private business to a listed company. In many instances we will cornerstone the IPO or look to lead the process. In Atomo's case we lead the IPO.
- ✓ We have continued our support since the IPO and are a substantial shareholder. We continue to hold the bulk our investment as we believe there are strong tailwinds for Rapid Device Testing, and Atomo has the world leading technology in this space. Atomo is a clear beneficiary of the COVID testing requirements. We believe this may result in an acceleration to profitability for Atomo and they can then use the cash for upcoming tests or potentially M&A.


Pleasingly for the fund we are expecting the upcoming quarter to be very active with at least three of our private businesses likely to transition to public companies. These include: Aroa, 4D Medical and DUG. The following pages detail 4DX and Aroa in greater depth.

## Returns Since Inception<sup>1</sup> Net of Fees (%)



<sup>1</sup> Inception date of the Trust is 19 August 2019. Performance shown net of fees. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

## Current Allocation



## Investment Activity – Selected Highlights

### 4D Medical (4DX)

Sector  
Healthcare

Investment Stage  
Pre-IPO / IPO

Brief Description  
4D Imaging Software



In the December 2019 quarterly review we wrote about 4DX. Our initial investment in 4DX was at the pre-IPO stage, in which we led the funding round. The company is in the process of lodging its prospectus and is likely to list in August 2020. 4DX is a highly innovative company focused on commercialising its four dimensional lung imaging technology. 4DX's software has the ability to create a step change in the capacity of physicians to diagnose and manage patients with lung disease. The software couples X-ray imaging with airflow analysis to identify respiratory deficiencies far earlier and with greater sensitivity in comparison to existing technologies. We initially invested for the following reasons:

- ✓ The management and board are experienced, fervent and strongly aligned. The founder Andreas is incredibly passionate, commercial and deeply invested. The company also has a strong board led by Bruce Rathie (former Chairman of Polynovo) and strong advisors including Sam Hupert (founder and CEO of pro-medicus)
- ✓ The software is commercially ready and can scale rapidly
- ✓ We particularly like medical technology companies that do not change the way a doctor "operates" but rather enhances their work. 4DX uses existing X-ray technologies and significantly enhances the images through its proprietary software.

We have been extremely pleased with the company's progress since our initial investment and are excited to lead the IPO funding. The key milestone achieved since the pre-IPO was the successful clearance from the Food and Drug Administration (FDA). FDA clearance was paramount for 4DX as it enables them to commercialise the product more broadly in the USA. Importantly the FDA approval has greater scope than originally anticipated which is hugely beneficial for 4DX. At this stage 4DX is not diagnosing any specific disease but is rather identifying if there is something abnormal with the lung through its XV ventilation analysis.

In a similar manner to Atomo we will support 4DX through its transition from a private business to a public company, and are contributing more capital at the IPO. 4DX has some significant milestones ahead which we are excited about, including:

- ✓ The XV Ventilation product launch in the US
- ✓ Large customer contract wins in the US and other markets
- ✓ Further regulatory approvals including both TGA and CE mark
- ✓ Ongoing product development

## Aroa

<b>Sector</b> Healthcare	<b>Investment Stage</b> Pre-IPO / IPO	<b>Brief Description</b> Tissue regeneration
-----------------------------	--	---



Aroa Biosurgeries is a pre-IPO position within the fund that is likely to IPO at the end of July 2020. Aroa is a soft tissue regeneration company that was founded in 2008. The company generated revenue of NZD22m in FY20 and has been EBITDA positive in FY19 and FY20. We invested in Aroa at both the pre-IPO and have added further capital into the IPO for the following reasons:

- ✓ The management is very experienced led by the founder and CEO Brian Ward. Brian is strongly aligned with over 11% ownership post IPO.
- ✓ The product is proven in the market with established revenues and strong gross margins.
- ✓ Aroa has excellent sales partners in the US enabling them to scale quickly. Along with this Aroa has a strong pipeline of new products. We believe Aroa can plug these new products into its existing sales channels which will allow for a faster go to market strategy.
- ✓ Aroa IPOs valuation is at a deep discount to listed ASX peers Polynovo (ASX: PNV) and Avita Medical (ASX: AVH). The table below illustrates this

Company	EV/Sales (FY20)
Aroa	8.4x
PNV	98.0x
AVH	52.0x

## Other Operational Updates

- **Spire:** Spire is our largest pre-IPO position. Pleasingly they won a material contract with NASA. The deal is worth USD7m for one year, with the option to extend. Spire will provide NASA with radio occultation data for earth observing missions and weather tracking. This is an incredibly exciting and ground breaking contract for Spire which could prove to be a strong reference point for further contract wins. ([Click here for a link to the Washington Post article](#)).
- **Lumitron:** Lumitron is our largest unlisted growth stage position. US Defence Advanced Research projects Agency (DARPA) awarded Lumitron an initial 24 month funding contract to develop a Tunable Gamma Ray Inspection Technology. This is both material in terms of the cash injection Lumitron will receive but also paves the way for potential commercial contracts to be won with both DARPA and the US defence force. ([Click here for a link to the DARPA article](#)).
- **Koala.com:** Koala has seen a surge in demand for its entire range of products in Australia during the COVID period. Along with this Koala experienced a boom in sales in Japan. This is incredible encouraging as Koala is now a diversified e-commerce furniture company in both Australia and Japan.
- **Aussie Broadband:** We wrote about Aussie Broadband's strong numbers in the March 2020 quarterly. Pleasingly the company has continued to experience record months into the June 2020 quarter. The company is in the process of finalising its prospectus and could IPO in the coming 3 - 4months.
- **Animoca Brands:** Animoca Brands is an innovative blockchain gaming company. The company has had a record quarter with AUD10.5m of revenue for the first four months in CY20. This included a positive EBITDA in April. The company also completed a raise of AUD6m from strategic investors with a converting price of 18c. With the proceeds of the raise they have made a small acquisition of nWay, which is a complementary gaming company.

## Outlook

---

We have been incredibly pleased with the performance of the fund to date, especially during a period of global volatility. We are expecting an exciting up coming quarter with a few of the private businesses likely to transition to the public market. We are also pleased with the progress of our growth stage businesses (e.g Koala and Lumitron). All our unlisted growth and expansion businesses are still carried at cost with the unit price yet to reflect the significant earnings progress in some of these companies.

Thank you again for your interest in the Fund.

Yours sincerely,



**Andrew Smith**


Head of Smaller Companies & Micro Caps  
Perennial Value



**Ryan Sohn**

Deputy Portfolio Manager  
Perennial Value

## Contact Us

 Level 27, 88 Phillip Street Sydney NSW 2000

 1300 730 032

 [invest@perennial.net.au](mailto:invest@perennial.net.au)

 [www.perennial.net.au](http://www.perennial.net.au)

Signatory of:



Issued by: The Investment Manager, Perennial Value Management Limited, ABN 22 090 879 904, AFSL: 247293. Trustee: Perennial Investment Management Limited ABN 13 108 747 637, AFSL: 275101. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation. While every effort has been made to ensure the information in this promotional statement is accurate; its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Gross performance does not include any applicable management fees or expenses. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. Contractual arrangements, including any applicable management fee, may be negotiated with certain large investors. Investments in the Trusts must be accompanied by an application form.